A carregar...
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitum...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3049870/ https://ncbi.nlm.nih.gov/pubmed/21135857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.226 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|